Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Nebraska Oncology Society
G

ES-SCLC 2020 Update: Which IO Options Showed Activity in Phase III Trials? How Effective Is Lurbinectedin in Stage IV Disease Progressed After 1L Therapy?

By Nebraska Oncology Society FEATURING Gregory Riely
By Nebraska Oncology Society FEATURING Gregory Riely
0 views
October 13, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy
Lung
16:46
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NRG-LU002 Trial - Maintenance Systemic Th…

Feat. P. Iyengar
14:26
Memorial Sloan Kettering Cancer Center

Radiation for Unresectable NSCLC: Where Are We Now and Where Are We …

Feat. D. Gomez
26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
14:52
Memorial Sloan Kettering Cancer Center

Advances in Resectable NSCLC

Feat. K. Gray
09:38
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "CDC7 Inhibition Constrains Lineage Plastic…

Feat. A. Quintanal-Villalonga
06:04
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "Durable Efficacy of Zenocutuzumab, a HER2 …

Feat. A. Schram
14:02
Insights from 2023 WCLC

WCLC 2023 Insights: "MSI and MMR-D Define a Distinct Subset of …

Feat. S. Yang
10:18
i3 Health

Additional Advances in Squamous NSCLC Research and Clinical Trials

Feat. M. Kris
08:03
i3 Health

New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertio…

Feat. H. Yu, M. Arcila
10:16
Memorial Sloan Kettering Cancer Center

2021 ASCO Updates on KEYLYNK-013 Study for Newly Diagnosed LS-SCLC: …

Feat. A. Rimner
05:59
Memorial Sloan Kettering Cancer Center

2021 ASCO Updates on METex14 Skipping mNSCLC: ctDNA Dynamics & R…

Feat. P. Paik
20:40
Memorial Sloan Kettering Cancer Center

Can TTFields with Chemotherapy Improve Clinical Outcome in the First…

Feat. C. Simone II
17:52
Memorial Sloan Kettering Cancer Center

Malignant Pleural Mesothelioma: What Do Clinical Trials Suggest on A…

Feat. M. Zauderer
16:53
Memorial Sloan Kettering Cancer Center

Should We Combine EGFR TKIs With Upfront Radiation Therapy in EGFR+ …

Feat. K. Beal
21:24
GRACE

Is There a Role for IO in EGFR+ Metastatic Lung Cancer?

Feat. H. Yu
19:58
Beacon Medical Interchange

Current Practice & Challenges in Execution of Genomic Testing in…

Feat. J. West, G. Riely
28:12
Beacon Medical Interchange

Should Local Ablation Therapy in Oligometastatic or Oligoprogressing…

Feat. J. West, G. Riely
23:26
CancerGRACE

EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC

Feat. H. Yu
09:30
GRACE

Q&A on EGFR Initial Treatment and Acquired Resistance in Advance…

Feat. H. Yu
07:39
Nebraska Oncology Society

ES-SCLC 2020 Update: Which IO Options Showed Activity in Phase III T…

Feat. G. Riely
16:08
Nebraska Oncology Society

Stage IV NSCLC 2020 Update: Is There a Benefit to Short-Course Chemo…

Feat. G. Riely